Canada markets closed
  • S&P/TSX

    20,287.80
    -23.98 (-0.12%)
     
  • S&P 500

    4,395.26
    -23.89 (-0.54%)
     
  • DOW

    34,935.47
    -149.06 (-0.42%)
     
  • CAD/USD

    0.8019
    -0.0019 (-0.24%)
     
  • CRUDE OIL

    73.81
    +0.19 (+0.26%)
     
  • BTC-CAD

    51,993.16
    +3,444.94 (+7.10%)
     
  • CMC Crypto 200

    955.03
    +5.13 (+0.54%)
     
  • GOLD FUTURES

    1,812.50
    -18.70 (-1.02%)
     
  • RUSSELL 2000

    2,226.25
    -13.78 (-0.62%)
     
  • 10-Yr Bond

    1.2390
    -0.0300 (-2.36%)
     
  • NASDAQ

    14,672.68
    -105.59 (-0.71%)
     
  • VOLATILITY

    18.24
    +0.54 (+3.05%)
     
  • FTSE

    7,032.30
    -46.12 (-0.65%)
     
  • NIKKEI 225

    27,283.59
    -498.83 (-1.80%)
     
  • CAD/EUR

    0.6752
    -0.0006 (-0.09%)
     

Oracle, La-Z-Boy fall; General Motors, Rambus rise

·1 min read

NEW YORK (AP) — Stocks that traded heavily or had substantial price changes Wednesday:

Oracle Corp., down $4.56 to $77.08.

Investors were disappointed by the software maker's first-quarter profit forecast.

La-Z-Boy Inc., down $4.94 to $37.34.

The furniture company warned investors that supply chain problems and higher materials prices could hurt profit margins.

General Motors Co., up 95 cents to $61.76.

The auto maker will raise its spending on electric and autonomous vehicles and add two U.S. battery factories.

Carnival Corp., up 67 cents to $29.28.

The cruise operator's Cunard line gave investors an encouraging update on its plan to resume operations.

Elanco Animal Health Inc., up $1.17 to $35.98.

The animal health company is buying Kindred Biosciences for about $440 million.

Rambus Inc., up $1.67 to $21.94.

The memory chip designer is buying back $100 million of its stock and purchasing digital technology company PLDA.

Magnachip Semiconductor Corp., down $1.58 to 24.07.

The chip products maker received an order from the U.S. government to halt its sale to Wise Road Capital, pending a review.

Regeneron Pharmaceuticals Inc., down $3.91 to $523.58.

The biotechnology company slipped, despite encouraging results from a study of its COVID-19 treatment.

The Associated Press

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting